Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Biosimilars Biosimilar'

Biosimilars Biosimilar published presentations and documents on DocSlides.

Biosimilars Guideline – a Summary of the Industry Comments

Biosimilars Guideline – a Summary of the Industry Comments

  • marina-yarberry
  • 0 Slides

M Bredenhann | Nycomed | 19.11.10. BIOSIMILAR...

Application of Biosimilars in RA IN Clinical Practice:

Application of Biosimilars in RA IN Clinical Practice:

  • conchita-marotz
  • 0 Slides

Key Issues and Challenges.  . Introduction. Diff...

PSHP President’s Update

PSHP President’s Update

  • olivia-moreira
  • 0 Slides

PSHP Annual Assembly. October 28, 2015. Matt Scol...

National Pharmacy Practice

National Pharmacy Practice

  • debby-jeon
  • 0 Slides

Gene Dorr . Area Vice President, PBM Consulting. ...

Biosimilar Biological Products

Biosimilar Biological Products

  • luanne-stotts
  • 0 Slides

2016 . Clinical Investigator . Training Course. S...

Comparison of US/EU Biosimilar

Comparison of US/EU Biosimilar

  • myesha-ticknor
  • 0 Slides

Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...

U.S. Biosimilars: An Introduction

U.S. Biosimilars: An Introduction

  • calandra-battersby
  • 0 Slides

Disclaimers. :. By 2016, 7 of the top 10 pharmace...

Bio similars A Presentation

Bio similars A Presentation

  • kittie-lecroy
  • 0 Slides

By. ANSHUL . SHARMA. Graduate Research Scholar. D...

Biosimilars are effective and safe and should immediately replace innovator molecules in the NHS

Biosimilars are effective and safe and should immediately replace innovator molecules in the NHS

  • myesha-ticknor
  • 0 Slides

Dr Chris Deighton. Consultant Rheumatologist . Co...

Comparison of US/EU Biosimilar

Comparison of US/EU Biosimilar

  • aaron
  • 0 Slides

Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...

Phil Johnson MS RPh Safe School Meds, Principle Partner

Phil Johnson MS RPh Safe School Meds, Principle Partner

  • yoshiko-marsland
  • 0 Slides

Moffitt Cancer Center, Director of Pharmacy (Reti...

Latin American Physician Perspectives on Biosimilars

Latin American Physician Perspectives on Biosimilars

  • celsa-spraggs
  • 0 Slides

Presented at the . Latin American Biologics/Biosi...

Biosimilars in emerging markets- regulatory and Commercial considerations

Biosimilars in emerging markets- regulatory and Commercial considerations

  • jane-oiler
  • 0 Slides

OMIC Group. Biosimilars 2104. Hyderabad. India. 2...

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

Challenges in demonstrating biosimilarity and interchangeability of biosimilar products

  • calandra-battersby
  • 0 Slides

OMIC Group Biosimilars 2014. Hyderabad India. 27-...

The generic and biosimilar

The generic and biosimilar

  • alida-meadow
  • 0 Slides

perspective. Warwick Smith. Director General BGMA...

PSHP President’s Update

PSHP President’s Update

  • myesha-ticknor
  • 0 Slides

PSHP Annual Assembly. October 28, 2015. Matt Scol...

Building a Biosimilars Pathway in the U.S.

Building a Biosimilars Pathway in the U.S.

  • attentionallianz
  • 24 Slides

Richard . Dolinar. , MD. Endocrinologist, Chairman...

CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS

CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS

  • iamamercy
  • 26 Slides

Dr.G.Hima. . Bindu. ...

TEVA PHARMACEUTICALS

TEVA PHARMACEUTICALS

  • adah
  • 74 Slides

Athlani. Audrey ; . Durlin. Stéphanie ; Jauregu...

22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum

22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum

  • carla
  • 9 Slides

Adoption by CHMP for release for consultation24 Ma...

INSIGHTS INTO THE MARKET

INSIGHTS INTO THE MARKET

  • summer
  • 20 Slides

FOR INFLIXIMABTable of ContentsThe Evolving Landsc...

Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De

Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De

  • anastasia
  • 15 Slides

x0000x0000 x/Attxachexd /xBottxom x/BBoxx 3x014x33...

Improving Your Formulary and Denials Management

Improving Your Formulary and Denials Management

  • trinity
  • 35 Slides

Zinkeng Asonganyi, PharmD. Director of Pharmacy Se...

Budget impact and cost-effectiveness of oncology

Budget impact and cost-effectiveness of oncology

  • roxanne
  • 14 Slides

biosimilars. Prof. dr. Steven Simoens. Health econ...

Synergy Satellite Event - Biosimilars in colorectal cancer

Synergy Satellite Event - Biosimilars in colorectal cancer

  • mia
  • 16 Slides

– what's your gut feeling?. 25th Anniversary EAH...

Medicare Part B Step Therapy Programs

Medicare Part B Step Therapy Programs

  • elina
  • 10 Slides

Page 1 of 10 UnitedHealthcare Medicare Advantag...

NEUPOGEN filgrastim

NEUPOGEN filgrastim

  • gelbero
  • 5 Slides

GRANIX (tbo - filgrastim), NIVESTYM (filgrastim -...

Prescription Drug Resource Center

Prescription Drug Resource Center

  • roberts
  • 4 Slides

Generic Drug Substitution Laws May 3 , 2019 Compi...

1 Immunogenicity The key safety issue for biosimilars

1 Immunogenicity The key safety issue for biosimilars

  • gelbero
  • 29 Slides

Prof. Ibrahim A. . Alsarra. Professor . of . Phar...

Challenges in Assessing Therapeutic Equivalence of

Challenges in Assessing Therapeutic Equivalence of

  • thomas
  • 27 Slides

Nanosimilars. Beat . Flühmann. Global Lead NBCD ....

  What is the value of Real-World Evidence for Biosimilars?

  What is the value of Real-World Evidence for Biosimilars?

  • bitsy
  • 82 Slides

Disclaimer. This panel is moderated by Dr. Delphin...

Category 1: Defining Terms

Category 1: Defining Terms

  • jasmine
  • 76 Slides

Clue: . A biologic product with no clinically mean...

JMP for Biosimilars : Tools for Analytical Similarity

JMP for Biosimilars : Tools for Analytical Similarity

  • erica
  • 26 Slides

Sept 16, 2015. W. Heath Rushing, . Adsurgo. LLC. ...

Regulatory aspects and review

Regulatory aspects and review

  • mary
  • 33 Slides

of EMA authorized . biosimilars. Session “Biosim...

Biosimilars and biologics –

Biosimilars and biologics –

  • gelbero
  • 52 Slides

What does personalisation . mean . for you?. Ian N...

Copyright © 2024 DocSlides. All Rights Reserved